Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODYSSEY
NCT02259127Phase 3Completed
- Sponsor
- Penta Foundation
- Start
- Sep 2016
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by Penta Foundation. Started Sep 2016; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02259127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259127.